Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 174,343,696
  • Shares Outstanding, K 2,745,570
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.83
  • Price/Sales 4.41
  • Price/Cash Flow 11.03
  • Price/Book 4.37

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.25 +0.40%
on 03/22/17
66.80 -4.94%
on 03/01/17
-1.79 (-2.74%)
since 02/22/17
3-Month
58.56 +8.44%
on 12/30/16
66.80 -4.94%
on 03/01/17
+3.92 (+6.58%)
since 12/22/16
52-Week
52.44 +21.09%
on 04/01/16
66.80 -4.94%
on 03/01/17
+10.47 (+19.74%)
since 03/22/16

Most Recent Stories

More News
Merck Animal Health Completes Acquisition of Vallee S.A.

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallee S.A., a leading privately-held...

MRK : 63.50 (-0.64%)
The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA

The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA

NVDA : 108.07 (+2.04%)
MA : 111.45 (+0.67%)
MRK : 63.50 (-0.64%)
GE : 29.53 (+0.48%)
ZEPATIER® now covered in Quebec for the treatment of chronic hepatitis C

Merck Canada Inc. today announced that ZEPATIER(® )(elbasvir/grazoprevir) will be listed among the drugs covered by Quebec's health insurance board, the Régie de l'assurance maladie du Québec (RAMQ),...

MRK : 63.50 (-0.64%)
Top Research Reports for Merck, GE and Others

Top Research Reports for Merck, GE and Others

TGT : 53.58 (+0.36%)
PYPL : 43.19 (+1.29%)
NVDA : 108.07 (+2.04%)
MA : 111.45 (+0.67%)
MRK : 63.50 (-0.64%)
SPG : 165.40 (-2.11%)
GE : 29.53 (+0.48%)
Why Biotech Stock Gilead (GILD) Could Be a Value Trap

Gilead's (GILD) valuation looks compelling but is the company really poised for

CELG : 123.37 (-0.36%)
MRK : 63.50 (-0.64%)
GILD : 67.83 (+0.13%)
AMGN : 167.45 (+0.36%)
GSK : 42.28 (-0.09%)
Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded

Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.

AZN : 30.98 (+2.01%)
ENDP : 9.87 (-2.85%)
JNJ : 126.26 (-0.78%)
MRK : 63.50 (-0.64%)
AGN : 233.99 (-0.24%)
KPTI : 10.10 (-0.39%)
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication

Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior...

MRK : 63.50 (-0.64%)
AMGN : 167.45 (+0.36%)
PFE : 34.47 (+0.64%)
GSK : 42.28 (-0.09%)
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

CLDX : 3.24 (+2.21%)
MRK : 63.50 (-0.64%)
RHHBY : 31.5450 (+0.43%)
BMY : 56.36 (+1.17%)
Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA(R) (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics...

MRK : 63.50 (-0.64%)
The Volatile Alzheimer's Disease (AD) Pipeline Continues to Disappoint, Continually Reshaping Expectations for the Future Market Outlook

Decision Resources Group closely monitors the ever-changing Alzheimer's disease (AD) market. The last six months have seen clinical trial failures for a number of high-profile development programs including...

MRK : 63.50 (-0.64%)
LLY : 84.36 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 64.48
1st Resistance Point 63.99
Last Price 63.50
1st Support Level 63.13
2nd Support Level 62.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.